Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for MASLD in adults
IRCT20260917071089N1Phase 3Not yet recruiting
- Sponsor
- Ardabil University of Medical Sciences
- Start
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in metabolic dysfunction-associated steatotic liver disease (MASLD) comparing Empagliflozin plus exercise with Placebo plus exercise (2 arms). Primary endpoints: Liver enzyme levels, Indicators of insulin resistance and 3 more. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
empagliflozin
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on IRCT20260917071089N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260917071089N1.